EUVIMEDEUVIMED entdecken
Crossref

An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy

Yichao Lu, Nana Ma, Keman Cheng, Guangna Liu, Jie Liang, Chen Xu, Danrui Li, Cheng Cao, Xiaoyu Gao, Liting Chen, Xinwei Wang, Yazhou Wang und 2 weitere

Advanced Materials · 2025-02 · 37 (8)

DOI: 10.1002/adma.202413392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 15.01.2025. Verfasst von Yichao Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, 210029, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, Antigen Presentation, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antigen‐presenting cells (APCs) process tumor vaccines and present tumor antigens as the first signals to T cells to activate anti‐tumor immunity, which process requires the assistance of co‐stimulatory second signals on APCs. The immune checkpoint programmed death ligand 1 (PD‐L1) not only mediates the immune escape of tumor cells but also acts as a co‐inhibitory second signal on APCs. The serious dysfunction of second signals due to the high expression of PD‐L1 on APCs in the tumor body results in the inefficiency of tumor vaccines. To overcome this challenge, a previously established Plug‐and‐Display tumor vaccine platform based on bacterial outer membrane vesicles (OMVs) is developed into an “Antigen Presentation Signal Enhancer” (APSE) by surface‐modifying PD‐L1 antibodies (αPD‐L1). While delivering tumor antigens, APSE can activate the expression of co‐stimulatory second signals in APCs due to the high immunogenicity of OMVs. More importantly, the surface‐modified αPD‐L1 binds to the co‐inhibitory signals PD‐L1, potentially restoring CD80 function and ensuring efficient co‐stimulatory second signals and activation of anti‐tumor immunity. The results reveal the importance of PD‐L1 blockage in the initiation process of anti‐tumor immunity, and the second signal modulation capability of APSE can expand the application potential of cancer vaccines to less immunogenic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesImmunotherapyAntigen PresentationNeoplasmsAnimalsB7-H1 AntigenMiceHumansAntigen-Presenting CellsCell Line, TumorAntigens, NeoplasmNanovaccines

Stichwörter der Autor:innen

PD‐L1 antibodyantigen presentation signalsbacterial outer membrane vesiclescancer vaccinessecond signals

Substanzen

Cancer VaccinesB7-H1 AntigenAntigens, NeoplasmNanovaccines

Autor:innen und Institutionen

  • Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, 210029, China.
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, No.11 Zhongguancun Beiyitiao, Beijing, 100190, China.
  • IGDB-NCNST Joint Research Center, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China.
  • Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, 155…

ORCID-Profile: Xiao Zhao

Förderung

  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • Beijing Nova Program
  • CAS Project for Young Scientists in Basic Research
  • Innovation Capability Development Project of Jiangsu Province
  • Jiangsu Province Capability Improvement Project through Science, Technology and Education (Jiangsu Provincial Medical Key Discipline)
  • National Key Research and Development Program of China

Zitieren

APA

Lu, Y., Ma, N., Cheng, K., Liu, G., Liang, J., Xu, C., Li, D., Cao, C., Gao, X., Chen, L., Wang, X., Wang, Y., Zhao, X., & Jiang, K. (2025). An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy. Advanced Materials, 37(8). https://doi.org/10.1002/adma.202413392

Vancouver

Lu Y, Ma N, Cheng K, Liu G, Liang J, Xu C, et al. An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy. Advanced Materials. 2025;37(8). doi:10.1002/adma.202413392

BibTeX
@article{Lu2025,
  author = {Lu, Yichao and Ma, Nana and Cheng, Keman and Liu, Guangna and Liang, Jie and Xu, Chen and Li, Danrui and Cao, Cheng and Gao, Xiaoyu and Chen, Liting and Wang, Xinwei and Wang, Yazhou and Zhao, Xiao and Jiang, Kuirong},
  title = {An OMV‐Based Nanovaccine as Antigen Presentation Signal Enhancer for Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {8},
  doi = {10.1002/adma.202413392}
}
Kostenlos starten →